Donate For Public and Patients Store Search

S033 - Cosmetics

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the importance of combination modalities in obtaining successful cosmetic outcomes
  • Examine the different combination modalities: combination topicals, topicals with device, topicals with injectable, injectable and device, combination hair treatments
  • Design, develop and communicate regimens for a diverse patient population. Incorporating technology, availability and efficacy

Description

The 2019 Cosmetics symposium continues to heighten awareness regarding the latest evidence-based medicine trends and practices in Cosmetic Dermatology. The participant will learn to recognize the importance of combination modalities in obtaining successful cosmetic outcomes. This will be achieved by examining the different combination modalities: combination topical, topical with device, topical with injectable, injectable with device and combination hair treatments. Lastly, the goal is to promote the participants security to design, develop and communicate regimens for a diverse patient population incorporating technology, availability and efficacy.

Disclosures

  • Callender, Valerie D., MD: Aerolase – A(H); Allergan, Inc – I(Grants/Research Funding), SP(H); Allergan, Inc. – C(H); Almirall – SP(H); Dermira – SP(H); Eli Lilly and Company – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Merz Aesthetics – Speaker/Faculty Education(H); Othro Dermatologics – I(Grants/Research Funding); PCA SKIN – A(H); Pfizer Inc. – I(Grants/Research Funding), SP(H); Unilever Home & Personal Care USA – A(H);
  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAƑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Farris, Patricia, MD: Aclaris Therapeutics Inc. – A(H); Bausch Health – A(H); Dermira – SP(H); La Roche-Posay Laboratorie Pharmaceutique – A(H); Neostrata – C(H); Nestle – C(H); Nutraceutical Wellness, LLC. – A(SO); Regimen MD – F(ST); Sente Labs – SP(H); SkinCeauticals LLC – A(H); U.SK Under Skin – C(Fees);
  • Glaser, Dee Anna, MD: Allergan, Inc. – I(Grants/Research Funding), O(H); American Society of Dermatologic Surgery – B(NC); Atacama Therapeutics – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding), Speaker/Faculty Education(H); Galderma Laboratories, L.P. – A(H); Galderma Research & Development, LLC – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H);
  • Roberts, Wendy E., MD: Aerolase – Speaker/Faculty Education(H); Allergan, Inc. – C(H); Cosmetic Bootcamp – A(H); Generational Dermatology Inc – F(NC); Lumisque – SP(H); Othro Dermatologics – A(H); SkinCeauticals LLC – A(H); Theraplex – A(NC); TopMD – A(NC); Vitalize Hair – C(S);
  • Sadick, Neil S., MD: Aclaris Therapeutics Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), O(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H); Derm Advance – SH(SO); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Incyte Corporation – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Pfizer Inc. – I(Grants/Research Funding); Philips Healthcare – I(Grants/Research Funding); Prescriber's Choice – O(H); Regeneron – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Sol-Gel Technologies – I(Grants/Research Funding); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Taylor, Susan C., MD: Aclaris Therapeutics, Inc. – A(H), I(Grants/Research Funding), SP(H); Allergan, Inc – A(H), Speaker/Faculty Education(NC); Almirall – A(H); Avon Products, Inc. – C(H); Beiersdorf, Inc. – A(H), C(H), Speaker/Faculty Education(H); Boots – A(H); CannTec – B(H); Croma-Pharma GmbH Austria – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H); Galderma Laboratories, LP – Speaker/Faculty Education(H); Johnson & Johnson Consumer Products Company – A(H); KGL Skin Study Center – Independent Contractor(S); Neostrata – C(H); Unilever – SP(H);
Schedule
Saturday, March 2
1:00 PM
Dr. Roberts / Introduction to Cosmetics
1:05 PM
Dr. Draelos / Optimizing Cosmetic Outcomes Through Combination Therapy
1:25 PM
Dr. Taylor / Photoprotection in conjunction with topical and oral treatment of pigmentary disorders.
1:45 PM
Dr. Farris / Synergistic Cosmecutical and Nutraceutical ingredients that make sense
2:05 PM
Dr. Roberts / Winning Combinations: Microdermabrasion, Microneedling, Peels
2:25 PM
Dr. Callender / Combination Cosmetic Treatments for Skin of Color patients with a focus on safety
2:45 PM
Dr. Glaser / Combining Neuromodulaters and Fillers
3:05 PM
Dr. Sadick / Combination Therapy with Energy-based Devices for Whole Body Rejuvenation
3:25 PM
Dr. Callender / Cosmetics Summary Q and A
3:45 PM
All faculty / Q and A
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 146A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Wendy E. Roberts, MD, FAAD
Speakers
  • Dee Anna Glaser, MD, FAAD
  • Neil S. Sadick, MD, FAAD
  • Patricia Farris, MD, FAAD
  • Susan C. Taylor, MD, FAAD
  • Valerie D. Callender, MD, FAAD
  • Zoe Diana Draelos, MD, FAAD - Handout